Biomarkers of response to treatment in acromegaly

References

• Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the Current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332. doi: 10.1210/er.2018-00115
   PubMed Web of Science ®Google Scholar
• Kasuki L, Rocha PDS, Lamback EB, et al. Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metab. 2019;63(6):630–637. doi: 10.20945/2359-3997000000193
   PubMed Web of Science ®Google Scholar
• Kasuki L, Antunes X, Lamback EB, et al. Acromegaly: update on management and long-term morbidities. Endocrinol Metab Clin North Am. 2020;49(3):475–486. doi: 10.1016/j.ecl.2020.05.007
   PubMed Web of Science ®Google Scholar
• Falch CM, Dupont AK, Olarescu NC, et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wien). 2023;165(10):3003–3010. doi: 10.1007/s00701-023-05772-7
   PubMedGoogle Scholar
• Guo X, Zhang R, Zhang D, et al. Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients. J Neurosurg. 2022;137(3):1–11. doi: 10.3171/2021.11.JNS212137
   Web of Science ®Google Scholar
• Antunes X, Ventura N, Camilo GB, et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine. 2018;60(3):415–422. doi: 10.1007/s12020-018-1590-8
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. 2022;107(2):297–308. doi: 10.1210/clinem/dgab726
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–108. doi: 10.1007/s11102-017-0791-0
   PubMed Web of Science ®Google Scholar
• Kasuki L, Wildemberg LE, Gadelha MR. MANAGEMENT of ENDOCRINE DISEASE: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018;178(3):R89–R100. doi: 10.1530/EJE-17-1006
   PubMedGoogle Scholar
• Gliga MC, Tătăranu LG, Popescu M, et al. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review. Rom J Morphol Embryol. 2023;64(1):25–33. doi: 10.47162/RJME.64.1.03
   PubMed Web of Science ®Google Scholar
• Berton AM, Prencipe N, Bertero L, et al. Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study. J Clin Med. 2022;12(1):12. doi: 10.3390/jcm12010025
   PubMed Web of Science ®Google Scholar
• Puig-Domingo M, Gil J, Sampedro-Nuñez M, et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27:375–389. doi: 10.1530/ERC-18-0565
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Trivellin G, Hernández Ramírez LC, et al. Genetics of pituitary adenomas. Front Horm Res. 2013;41:111–140.
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Giampietro A, Gessi M, et al. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs. J Neuroendocrinol. 2023;35(4):e13263. doi: 10.1111/jne.13263
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013;24(5):238–246. doi: 10.1016/j.tem.2012.11.007
   PubMed Web of Science ®Google Scholar
• Coelho MCA, Vasquez ML, Wildemberg LE, et al. Clinical significance of filamin a in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Sci Rep. 2019;9(1):1122. doi: 10.1038/s41598-018-37692-3
   PubMed Web of Science ®Google Scholar
• Herkenhoff CGB, Trarbach EB, Batista RL, et al. Survivin: a potential Marker of resistance to somatostatin receptor ligands. J Clin Endocrinol Metab. 2023;108(4):876–887. doi: 10.1210/clinem/dgac610
   PubMedGoogle Scholar
• Henriques DG, Miranda RL, Dezonne RS, et al. miR-383-5p, miR-181a-5p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly. Int J Mol Sci. 2023;24(3):24. doi: 10.3390/ijms24032875
   Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66–71. doi: 10.1210/jc.2012-2609
   PubMed Web of Science ®Google Scholar
• Luque RM, Ibáñez-Costa A, Neto LV, et al. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett. 2015;359(2):299–306. doi: 10.1016/j.canlet.2015.01.037
   PubMed Web of Science ®Google Scholar
• Ilie MD, Tabarin A, Vasiljevic A, et al. Predictive Factors of somatostatin receptor ligand response in acromegaly-A prospective study. J Clin Endocrinol Metab. 2022;107:2982–2991. doi: 10.1210/clinem/dgac512
   PubMed Web of Science ®Google Scholar
• Manosso KZB, Sampaio CL, Kasuki L, et al. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. Endocrine. 2021;74(1):146–154. doi: 10.1007/s12020-021-02766-2
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247–271. doi: 10.1210/er.2010-0002
   PubMed Web of Science ®Google Scholar
• Durmuş ET, Atmaca A, Kefeli M, et al. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res. 2022;67:101502. doi: 10.1016/j.ghir.2022.101502
   PubMed Web of Science ®Google Scholar
• Biagetti B, Iglesias P, Villar-Taibo R, et al. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Front Endocrinol. 2022;13:984877. doi: 10.3389/fendo.2022.984877
   PubMed Web of Science ®Google Scholar
• Coopmans EC, Korevaar TIM, van Meyel SWF, et al. Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. 2020;105:2964–2974. doi: 10.1210/clinem/dgaa387
   Web of Science ®Google Scholar
• Wildemberg LE, da Silva Camacho AH, Miranda RL, et al. Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. J Clin Endocrinol Metab. 2021 Mar;4:dgab125.
   Google Scholar
• Gatto F, Arvigo M, Ferone D. Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest. 2020;43(11):1543–1553. doi: 10.1007/s40618-020-01335-0
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest. 2013;36(1):38–43. doi: 10.3275/8305
   PubMed Web of Science ®Google Scholar
• Fischer T, Doll C, Jacobs S, et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab. 2008;93(11):4519–4524. doi: 10.1210/jc.2008-1063
   PubMed Web of Science ®Google Scholar
• Gatto F, Wildemberg LE, Ferone D, et al. Routine evaluation of somatostatin receptor type 2 in patients with acromegaly: do we still need more evidence? J Clin Endocrinol Metab. 2022;107(12):e4382–e4383. doi: 10.1210/clinem/dgac584
   PubMed Web of Science ®Google Scholar
• Venegas-Moreno E, Vazquez-Borrego MC, Dios E, et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med. 2018;22(3):1640–1649. doi: 10.1111/jcmm.13440
   PubMed Web of Science ®Google Scholar
• Plockinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008;93(4):1203–1210. doi: 10.1210/jc.2007-1986
   PubMed Web of Science ®Google Scholar
• World Health O. International agency for research on C, board WHOCoTE. central nervous system tumours. Lyon: International Agency for Research on Cancer, World Health Organization; 2021.
   Google Scholar
• Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82–91. doi: 10.1007/s12022-008-9029-z
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Carmichael JD, Cooper O, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122–131. doi: 10.1210/jc.2014-2468
   PubMed Web of Science ®Google Scholar
• Larkin S, Reddy R, Karavitaki N, et al. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol. 2013;168:491–499. doi: 10.1530/EJE-12-0864
   PubMed Web of Science ®Google Scholar
• Mayr B, Buslei R, Theodoropoulou M, et al. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol. 2013;169(4):391–400. doi: 10.1530/EJE-13-0134
   PubMed Web of Science ®Google Scholar
• Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates to clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76:96–102. doi: 10.1111/j.1365-2265.2011.04163.x
   PubMed Web of Science ®Google Scholar
• Brzana J, Yedinak CG, Gultekin SH, et al. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16(4):490–498. doi: 10.1007/s11102-012-0445-1
   PubMed Web of Science ®Google Scholar
• Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005;90(11):6290–6295. doi: 10.1210/jc.2005-0998
   PubMed Web of Science ®Google Scholar
• Kiseljak-Vassiliades K, Carlson NE, Borges MT, et al. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. 2015;49(1):231–241. doi: 10.1007/s12020-014-0383-y
   PubMed Web of Science ®Google Scholar
• Hernández-Ramírez LC. Potential markers of disease behavior in acromegaly and gigantism. Expert Rev Endocrinol Metab. 2020;15(3):171–183. doi: 10.1080/17446651.2020.1749048
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–383. doi: 10.1210/jc.2009-2556
   PubMed Web of Science ®Google Scholar
• Daly AF, Rostomyan L, Betea D, et al. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect. 2019;8(4):367–377. doi: 10.1530/EC-19-0004
   PubMed Web of Science ®Google Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72–78. doi: 10.1111/j.1365-2265.2011.04286.x
   PubMed Web of Science ®Google Scholar
• Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973–4978. doi: 10.1210/jc.2010-0573
   PubMed Web of Science ®Google Scholar
• Heck A, Emblem KE, Casar-Borota O, et al. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52(2):333–343. doi: 10.1007/s12020-015-0766-8
   PubMed Web of Science ®Google Scholar
• Potorac I, Petrossians P, Daly AF, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer. 2016;23(11):871–881. doi: 10.1530/ERC-16-0356
   PubMed Web of Science ®Google Scholar
• Kocak B, Durmaz ES, Kadioglu P, et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731–2739. doi: 10.1007/s00330-018-5876-2
   PubMed Web of Science ®Google Scholar
• Potorac I, Beckers A, Bonneville JF. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary. 2017;20(1):116–120. doi: 10.1007/s11102-017-0788-8
   PubMed Web of Science ®Google Scholar
• Casarini AP, Jallad RS, Pinto EM, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary. 2009;12:297–303. doi: 10.1007/s11102-009-0175-1
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158:295–303. doi: 10.1530/EJE-07-0562
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009;94(7):2634–2643. doi: 10.1210/jc.2008-2564
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95:2497–2502. doi: 10.1210/jc.2009-2247
   PubMed Web of Science ®Google Scholar
• Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013;169:217–223. doi: 10.1530/EJE-13-0349
   PubMed Web of Science ®Google Scholar
• Fusco A, Zatelli MC, Bianchi A, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab. 2008;93(7):2746–2750. doi: 10.1210/jc.2008-0126
   PubMed Web of Science ®Google Scholar
• Venegas-Moreno E, Flores-Martinez A, Dios E, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019;23(5):3088–3096. doi: 10.1111/jcmm.13851
   PubMed Web of Science ®Google Scholar
• Gil J, Jordà M, Soldevila B, et al. Epithelial-mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly. Front Endocrinol. 2021;12:646210. doi: 10.3389/fendo.2021.646210
   PubMed Web of Science ®Google Scholar
• Puig Domingo M. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf). 2015;83(1):3–14. doi: 10.1111/cen.12731
   PubMed Web of Science ®Google Scholar
• Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol. 2017;235(3):R101–R116. doi: 10.1530/JOE-17-0254
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012;19:L25–29. doi: 10.1530/ERC-12-0020
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241–250. doi: 10.1530/EJE-15-0832
   PubMed Web of Science ®Google Scholar
• Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012;97:E1411–1420. doi: 10.1210/jc.2012-1111
   PubMed Web of Science ®Google Scholar
• Ballarè E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86(8):3809–3814. doi: 10.1210/jcem.86.8.7787
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders R, van der Pas R, et al. β-arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology. 2013;154:4715–4725. doi: 10.1210/en.2013-1672
   PubMed Web of Science ®Google Scholar
• Coelho MCA, Vasquez ML, Wildemberg LE, et al. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly. J Cell Mol Med. 2018;22(4):2110–2116. doi: 10.1111/jcmm.13427
   PubMed Web of Science ®Google Scholar
• Fougner SL, Bollerslev J, Latif F, et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab. 2008;93(4):1211–1216. doi: 10.1210/jc.2007-2272
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Tichomirowa MA, Sievers C, et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer. 2009;125(9):2122–2126. doi: 10.1002/ijc.24602
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Henriques D, Elias PCL, et al. Gsp mutation is not a Molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly. Cancers (Basel). 2021;13(19):4857. doi: 10.3390/cancers13194857
   PubMed Web of Science ®Google Scholar
• Denes J, Kasuki L, Trivellin G, et al. Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS One. 2015;10(2):e0117107. doi: 10.1371/journal.pone.0117107
   PubMed Web of Science ®Google Scholar
• Bogner EM, Daly AF, Gulde S, et al. miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int J Cancer. 2020;147(12):3523–3538. doi: 10.1002/ijc.33268
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, da Silva Camacho AH, Miranda RL, et al. Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. J Clin Endocrinol Metab. 2021;106(7):2047–2056. doi: 10.1210/clinem/dgab125
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Biller BMK, Freda PU, et al. A pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. doi: 10.1007/s11102-020-01091-7
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine. 2014;46(2):220–225. doi: 10.1007/s12020-014-0183-4
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667–678. doi: 10.1007/s11154-020-09588-z
   PubMed Web of Science ®Google Scholar
• Grasso LFS, Auriemma RS, Pivonello R, et al. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. Expert Rev Endocrinol Metab. 2017;12(1):73–85. doi: 10.1080/17446651.2016.1222899
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–1335. doi: 10.1210/jc.2010-2443
   PubMed Web of Science ®Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561. doi: 10.1038/s41574-018-0058-5
   PubMed Web of Science ®Google Scholar
• Kasuki L, Dalmolin MD, Armondi Wildemberg LE, et al. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol (Oxf). 2018 Mar 9;88(6):889–895. Epub ahead of print. doi:10.1111/cen.13595.
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2013;16(1):101–108. doi: 10.1007/s11102-012-0382-z
   PubMed Web of Science ®Google Scholar
• Sherlock M, Fernandez-Rodriguez E, Alonso AA, et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab. 2009;94(4):1255–1263. doi: 10.1210/jc.2008-1420
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Kasuki L, Gadelha MR. Precision medicine in the medical management of pituitary tumors. Curr Opin Endocr Metab Res. 2018;1:57–62. doi: 10.1016/j.coemr.2018.02.001
   Google Scholar
• Ramos-Levi AM, Bernabeu I, Sampedro-Nunez M, et al. Genetic predictors of response to different medical therapies in acromegaly. Prog Mol Biol Transl Sci. 2016;138:85–114.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Dalmolin MD, Wildemberg LE, et al. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol (Oxf). 2018;88(6):889–895. doi: 10.1111/cen.13595
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother. 2016;17(4):579–588. doi: 10.1517/14656566.2016.1146688
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799. doi: 10.1210/jc.2013-2480
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884. doi: 10.1016/S2213-8587(14)70169-X
   PubMed Web of Science ®Google Scholar
• Shimon I, Adnan Z, Gorshtein A, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62(2):448–455. doi: 10.1007/s12020-018-1690-5
   PubMed Web of Science ®Google Scholar
• Marques NV, Wildemberg LEA, Gadelha MR. Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly. Endocr Connect. 2023;12(10):12. doi: 10.1530/EC-23-0155
   Web of Science ®Google Scholar
• Gadelha M, Marques NV, Fialho C, et al. Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years’ single-center real-world experience. J Clin Endocrinol Metab. 2023;108(12):e1571–e1579. doi: 10.1210/clinem/dgad378
   PubMedGoogle Scholar
• Lim DST, Fleseriu M. Personalized medical treatment of patients with acromegaly: a review. Endocr Pract. 2022;28(3):321–332. doi: 10.1016/j.eprac.2021.12.017
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol. 2021;184(2):217–229. doi: 10.1530/EJE-20-0767
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, Franck SE, et al. In vitro head-to-head comparison between octreotide and pasireotide in GH-Secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102(6):2009–2018. doi: 10.1210/jc.2017-00135
   PubMed Web of Science ®Google Scholar
• Coopmans EC, Schneiders JJ, El-Sayed N, et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605. doi: 10.1530/EJE-19-0840
   PubMedGoogle Scholar
• Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab. 2019;104(3):915–924. doi: 10.1210/jc.2018-01524
   PubMed Web of Science ®Google Scholar
• Ruiz S, Gil J, Biagetti B, et al. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf). 2023;99(4):378–385. doi: 10.1111/cen.14946
   PubMedGoogle Scholar
• Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23(5):623–646. doi: 10.1210/er.2001-0022
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, Huayllas MKP, Vilar L, et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch Endocrinol Metab. 2019;63:328–336. doi: 10.20945/2359-3997000000159
   PubMed Web of Science ®Google Scholar
• Buchfelder M, van der Lely AJ, Biller BMK, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419–427. doi: 10.1530/EJE-18-0616
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754–1759. doi: 10.1016/S0140-6736(01)06844-1
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171–1177. doi: 10.1056/NEJM200004203421604
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164:325–333. doi: 10.1530/EJE-10-0867
   PubMed Web of Science ®Google Scholar
• Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009;161(1):21–25. doi: 10.1530/EJE-08-0990
   PubMed Web of Science ®Google Scholar
• Sievers C, Baur DM, Schwanke A, et al. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary. 2015;18(6):916–923. doi: 10.1007/s11102-015-0673-2
   PubMed Web of Science ®Google Scholar
• Parkinson C, Burman P, Messig M, et al. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab. 2007;92(1):190–195. doi: 10.1210/jc.2006-1412
   PubMed Web of Science ®Google Scholar
• Droste M, Domberg J, Buchfelder M, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171(1):59–68. doi: 10.1530/EJE-13-0438
   PubMed Web of Science ®Google Scholar
• Franck SE, Broer L, van der Lely AJ, et al. The effect of the exon-3-deleted growth hormone receptor on pegvisomant-treated acromegaly: a systematic review and meta-analysis. Neuroendocrinology. 2017;105:131–140. doi: 10.1159/000448844
   PubMed Web of Science ®Google Scholar
• Kasuki L, Machado EO, Ogino LL, et al. Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch Endocrinol Metab. 2016;60:479–485. doi: 10.1590/2359-3997000000210
   PubMed Web of Science ®Google Scholar
• de Oliveira Machado E, Lima CH, Ogino LL, et al. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients. Pituitary. 2016;19:375–380. doi: 10.1007/s11102-016-0715-4
   PubMed Web of Science ®Google Scholar
• Franck SE, der Lely AJ V, Delhanty PJ, et al. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the growth hormone receptor deletion of exon 3. Eur J Endocrinol. 2015;173(5):553–561. Epub Aug 4. doi: 10.1530/EJE-15-0519
   PubMed Web of Science ®Google Scholar
• Filopanti M, Olgiati L, Mantovani G, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab. 2012;97:E165–172. doi: 10.1210/jc.2011-1769
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola C, Quinteiro C, et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab. 2010;95(1):222–229. doi: 10.1210/jc.2009-1630
   PubMed Web of Science ®Google Scholar
• Paniz-Mondolfi A, Guerra S, Munoz M, et al. Evaluation and validation of an RT-PCR assay for specific detection of monkeypox virus (MPXV). J Med Virol. 2023;95(1):e28247. doi: 10.1002/jmv.28247
   PubMed Web of Science ®Google Scholar
• Konig IR, Fuchs O, Hansen G, et al. What is precision medicine? Eur Respir J. 2017;50(4):50. doi: 10.1183/13993003.00391-2017
   Web of Science ®Google Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372:2229–2234. doi: 10.1056/NEJMsb1503104
   PubMed Web of Science ®Google Scholar
• Ku CR, Melnikov V, Zhang Z, et al. Precision therapy in acromegaly caused by pituitary tumors: how close is it to reality? Endocrinol Metab. 2020;35(2):206–216. doi: 10.3803/EnM.2020.35.2.206
   Google Scholar
• Bollerslev J, Heck A, Olarescu NC. MANAGEMENT of ENDOCRINE DISEASE: individualised management of acromegaly. Eur J Endocrinol. 2019;181(2):R57–R71. doi: 10.1530/EJE-19-0124
   PubMed Web of Science ®Google Scholar
• Kasuki L, Gadelha MR. Innovative therapeutics in acromegaly. Best Pract Res Clin Endocrinol Metab. 2022;36(6):101679. doi: 10.1016/j.beem.2022.101679
   PubMed Web of Science ®Google Scholar